^
Association details:
| Biomarker: | KIF13A-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First Case Report of a Novel KIF13A-ALK Fusion in a Lung Adenocarcinoma patients and Response to Alectinib with a 4-year follow-up
Published date:
12/01/2023
Excerpt:
This is the first reported case of a 74-year-old female with stage IV lung adenocarcinoma, featuring a novel Kinesin Family Member 13A (KIF13A)-ALK fusion, identified via next-generation sequencing (NGS) and confirmed with fluorescence in situ hybridization (FISH)....subsequent treatment with alectinib as a third-line option yielded positive results. A stable disease state persisted for an impressive 31 months of progression-free survival (PFS), accompanied by minimal toxicity symptoms.
DOI:
10.3389/fgene.2023.1289346
